Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis
暂无分享,去创建一个
D. Reich | A. Traboulsee | D. Li | E. Radue | D. Reich | E. Fisher | J. Simon | N. Richert | O. Khan | Jiwon Oh | C. Ford | L. Stone | J. Oh | S. Newsome | D. Jones | A. Malhotra | K. Rammohan | J. Halper | David E Jones | A. Malhotra | D.E. Jones | Daniel S. Reich | David K B Li
[1] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[2] S. Maderwald,et al. Diagnostic value of 3D fluid attenuated inversion recovery sequence in multiple sclerosis , 2015, Acta radiologica.
[3] James McIninch,et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients , 2014, Annals of clinical and translational neurology.
[4] F. Barkhof,et al. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. , 2014, Current opinion in neurology.
[5] R. Rudick,et al. Simple MRI Metrics Contribute to Optimal Care of the Patient with Multiple Sclerosis , 2014, American Journal of Neuroradiology.
[6] M. Eliasziw,et al. Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes , 2014, Multiple sclerosis.
[7] À. Rovira,et al. Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event , 2014, PloS one.
[8] F. Barkhof,et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[9] M. Rovaris. Faculty Opinions recommendation of Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. , 2013 .
[10] Douglas L Arnold,et al. Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[11] B Stubinski,et al. Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.
[12] Peter Reimer,et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines , 2013, European Radiology.
[13] R. Rudick,et al. Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.
[14] F. Barkhof,et al. Spinal cord lesions in patients with clinically isolated syndrome , 2013, Neurology.
[15] F. Fazekas,et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis , 2012, Journal of Neurology.
[16] M. Filippi,et al. Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy , 2012, Annals of neurology.
[17] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.
[18] D. Bluemke,et al. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines , 2012, Journal of Cardiovascular Magnetic Resonance.
[19] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[20] D. Goodin,et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome , 2011, Neurology.
[21] F. Moore. INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME , 2009, Neurology.
[22] C. Pozzilli,et al. One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.
[23] P. Calabresi,et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.
[24] J Sastre-Garriga,et al. Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.
[25] F. Barkhof,et al. High field MRI in the diagnosis of multiple sclerosis: high field–high yield? , 2009, Neuroradiology.
[26] Luca Roccatagliata,et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach , 2009, Annals of neurology.
[27] Anthony Traboulsee,et al. Conventional MR imaging. , 2008, Neuroimaging clinics of North America.
[28] Jeffrey A. Cohen,et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach , 2008, Multiple sclerosis.
[29] P. Rieckmann,et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations , 2008, Journal of Neurology.
[30] Melvin Greer,et al. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. , 2008, Archives of neurology.
[31] A. Thompson,et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.
[32] David H. Miller,et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation” , 2006, The Lancet Neurology.
[33] R. Rudick,et al. Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.
[34] J A Frank,et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. , 2006, AJNR. American journal of neuroradiology.
[35] F. Barkhof,et al. Spinal cord abnormalities in recently diagnosed MS patients , 2004, Neurology.
[36] A J Thompson,et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study , 2003, Journal of neurology, neurosurgery, and psychiatry.
[37] F. Jolesz,et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals , 2003, Neurology.
[38] David H. Miller,et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.
[39] S. Cole,et al. Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses , 2002 .
[40] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[41] F Barkhof,et al. T1 hypointensities and axonal loss. , 2000, Neuroimaging clinics of North America.
[42] N. Patronas,et al. Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.
[43] B E Kendall,et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.
[44] B. Waksman. A multiple sclerosis therapy? , 1987, Nature.
[45] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[46] R. Sergott. Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up , 2009 .
[47] P. Narayana,et al. Cervical Spinal Cord Lesions in Multiple Sclerosis: T1-weighted Inversion-Recovery MR Imaging with Phase-Sensitive Reconstruction. , 2008, Radiology.
[48] Hompson,et al. A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .
[49] S. Cole,et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. , 2002, Annals of neurology.
[50] U. Schmiedl,et al. Lesion enhancement in radio-frequency spoiled gradient-echo imaging: theory, experimental evaluation, and clinical implications. , 1994, AJNR. American journal of neuroradiology.